Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin

Trynda-Lemiesz, Lilianna; Kozłowski, Henryk; Keppler, Bernhard K.

doi:10.1016/s0162-0134(99)00183-x

Cited by 71 publications

(88 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, our data also show that trans-DDP exhibits higher binding to HSA than compound 2 and cis-DDP. So, it is likely that as previously reported for transplatin, inactivation of compound 1 through binding to serum albumin may also play an important role in the lack of in vivo antitumor activity shown by this drug (Trynda-Lemiesz et al, 1999). On the other hand, our in vivo studies on the extent of binding of compounds 1 and 2 to plasma proteins after i.p.…”

Section: Discussionsupporting

confidence: 49%

“…Albumin plays a central role in the molecular pharmacology of drugs used in cancer chemotherapy. In fact, HSA interferes with certain anticancer agents, changing their biological effectiveness (Trynda-Lemiesz et al, 1999). Figure 8 shows the binding of compounds 1, 2, cis-DDP, and trans-DDP to HSA as a function of incubation time over a 14-day period.…”

Section: Downloaded Frommentioning

confidence: 99%

See 1 more Smart Citation

Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex:trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)]

Pérez¹,

Kèlland²,

Montero³

et al. 2003

Molecular Pharmacology

View full text Add to dashboard Cite

The antitumor and cellular pharmacological properties of the trans-Pt(IV) complex, trans-[PtCl 2 (OH) 2 (dimethylamine)(isopropylamine)] (compound 2) has been evaluated in comparison with its corresponding trans-Pt(II) counterpart, trans-[PtCl 2 (dimethylamine)(isopropylamine)] (compound 1). The results reported here indicate that compound 2 markedly circumvents cisplatin resistance in 41McisR and CH1cisR ovarian tumor cell lines endowed with different mechanisms of resistance (decreased platinum accumulation and enhanced DNA repair/tolerance, respectively). However, compound 1 is able to circumvent cisplatin resistance only in CH1cisR cells. Interestingly, at equitoxic concentrations, compounds 1 and 2 induce a higher amount of apoptotic cells than cisplatin in CH1cisR cells. Moreover, the number of apoptotic cells induced by compounds 1 and 2 correlates with their ability to form DNA interstrand crosslinks in CH1cisR cells. Although compounds 1 and 2 showed remarkable cytotoxic activity, only compound 2 was able to inhibit the growth of CH1 human ovarian carcinoma xenografts in mice. Binding studies with serum albumin indicate that compound 1 possesses a much higher reactivity against albumin than compound 2. Moreover, the level of binding of compound 1 to plasma proteins during the period 15 min to 1 h after administration to mice (15 mg/kg, i.p.) is 2.5-fold higher than that of compound 2. Therefore, the lack of in vivo antitumor activity shown by compound 1 might be related to its extracellular inactivation before reaching the tumor site because of its high rate of binding to plasma proteins.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Downloaded Frommentioning

confidence: 99%

Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex:trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)]

Pérez¹,

Kèlland²,

Montero³

et al. 2003

Molecular Pharmacology

View full text Add to dashboard Cite

show abstract

“…The mode of action and the intracellular targets of Ru(III) complexes are not exactly known. There are many investigations suggesting that the intravenously injected drugs can be transported mainly by the serum albumin and/or transferrin in the blood plasma [14][15][16][17][18]. Reduction of Ru (III) compounds in the cytosol leads to the kinetically more labile and more reactive Ru (II) compounds.…”

Section: [Tetrachlorido(1h-imidazole)(dimethylsulfoxide-κs)ruthenate(mentioning

confidence: 99%

Solution equilibrium studies of anticancer ruthenium(II)-η6-p-cymene complexes of pyridinecarboxylic acids

et al. 2014

View full text Add to dashboard Cite

Stoichiometry and stability of antitumor ruthenium(II)-η 6 -p-cymene complexes of picolinic acid and its 6-methyl and 6-carboxylic acid derivatives were determined by pHpotentiometry, 1 H NMR spectroscopy and UV/Vis spectrophotometry in aqueous solution in the presence or absence of coordinating chloride ions. The picolinates form exclusively monoligand complexes in which they can coordinate via the bidentate (O,N) mode and a chloride or a water molecule is found at the third binding site of the ruthenium(II)-η 6 -p-cymene moiety depending on the conditions. [Ru(η 6 -p-cymene)(L)(H 2 O/Cl)] species are predominant at physiological pH in all studied cases. Hydrolysis of the aqua complex or the chlorido/hydroxido co-ligand exchange results in the formation of the mixed-hydroxido species [Ru(η 6 -p-cymene)(L)(OH)] in the basic pH range. There is no indication for the decomposition of the mono-ligand complexes during 24 h in the ruthenium(II)-η 6 -pcymene−picolinic acid system between pH 3 and 11; however, a slight dissociation with a low reaction rate was found in the other two systems leading to the appearance of the dinuclear trihydroxido-bridged species [Ru 2 (η 6 -p-cymene) 2 (OH) 3 ] + and free ligands at pH > 10. The replacement of the chlorido by an aqua ligand in [Ru(η 6 -p-cymene)(L)Cl] was also monitored and equilibrium constants for the exchange process were determined.

show abstract

“…This protein is a singlechain 66 kDa protein, which is largely α-helical, and consists of three structurally homologous domains (I-III) each of which is divided into two subdomains (A and B) (3,4). Similar to most of the plasma proteins, albumin synthesizes in the liver where it is produced at a rate of approximately 0.7 mg/h for every gram of liver.…”

Section: Introductionmentioning

confidence: 99%

Investigation of effects of newly synthesized Pt(II) complex against human serum albumin and leukemia cell line of K562

Divsalar¹,

Saboury²,

Ahadi³

et al. 2010

BMB Reports

View full text Add to dashboard Cite

Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin

Cited by 71 publications

References 21 publications

Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex:trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)]

Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex:trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)]

Solution equilibrium studies of anticancer ruthenium(II)-η6-p-cymene complexes of pyridinecarboxylic acids

Investigation of effects of newly synthesized Pt(II) complex against human serum albumin and leukemia cell line of K562

Contact Info

Product

Resources

About